Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patients
Autor: | Ai Takeda-Watanabe, Tomoe Nomura, Atsushi Nakagawa, Yasuto Tomita, Ranji Hayashi, Yasuharu Nakano, Munehiro Kitada, Hisakazu Shiroeda, Shin-ichi Tsuda, Takako Nagai, Takeo Kosaka, Keizo Kanasaki, Nobuhiko Ueda, Megumi Kanasaki, Daisuke Koya, Makoto Nishizawa, Kazunori Konishi, Hiroki Ito, Mizue Fujii |
---|---|
Rok vydání: | 2013 |
Předmět: |
medicine.medical_specialty
animal structures Ileus Endocrinology Diabetes and Metabolism Adverse drug reaction Blood sugar Case Report Pharmacology Glucagon Dipeptidyl peptidase Internal medicine Diabetes mellitus Internal Medicine medicine Adverse effect Dipeptidyl peptidase-4 Dipeptidyl peptidase‐4 business.industry digestive oral and skin physiology Articles General Medicine medicine.disease Clinical Science and Care Endocrinology Niveau business Complication |
Zdroj: | Journal of Diabetes Investigation |
ISSN: | 2040-1116 |
DOI: | 10.1111/jdi.12095 |
Popis: | Dipeptidyl peptidase (DPP)‐4 inhibitors are a new class of antidiabetic drugs that increase incretin hormone levels to enhance blood sugar level‐dependent insulinotropic effects, suppress glucagon action, and reduce bowel motility. These incretin effects are ideal for blood sugar control. However, the safety profile of DPP‐4 inhibitors is not yet established. Herein, we present three cases of ileus, considered to be closely related to the use of DPP‐4 inhibitors, in diabetic patients. Each of the three patients exhibited some risk of a deficiency in bowel movement; the onset of ileus was within 40 days after strengthened inhibition of DPP‐4. The use of a DPP‐4 inhibitor could be safe, although the cases presented herein enable us to inform the scientific community to some of the potential adverse effects of the use of DPP‐4 inhibitors in select populations. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |